(NASDAQ: GTHX) G1 Therapeutics's forecast annual revenue growth rate of 20.21% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.52%.
G1 Therapeutics's revenue in 2024 is $82,511,000.On average, 4 Wall Street analysts forecast GTHX's revenue for 2024 to be $3,587,925,347, with the lowest GTHX revenue forecast at $3,243,148,349, and the highest GTHX revenue forecast at $3,776,626,156. On average, 4 Wall Street analysts forecast GTHX's revenue for 2025 to be $5,493,829,620, with the lowest GTHX revenue forecast at $3,544,338,853, and the highest GTHX revenue forecast at $7,272,419,572.
In 2026, GTHX is forecast to generate $7,498,025,353 in revenue, with the lowest revenue forecast at $4,075,728,684 and the highest revenue forecast at $9,894,395,133.